

(19) World Intellectual Property
Organization
International Bureau



14 OCT 2004

(43) International Publication Date
6 November 2003 (06.11.2003)

PCT

(10) International Publication Number
WO 2003/090690 A3

(51) International Patent Classification⁷: **C07F 9/40**,
9/02, 9/38

(21) International Application Number:
PCT/US2003/012901

(22) International Filing Date: 25 April 2003 (25.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/375,665 26 April 2002 (26.04.2002) US
60/375,834 26 April 2002 (26.04.2002) US
60/375,779 26 April 2002 (26.04.2002) US
60/375,622 26 April 2002 (26.04.2002) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/375,665 (CON)
Filed on	26 April 2002 (26.04.2002)
US	60/375,834 (CON)
Filed on	26 April 2002 (26.04.2002)
US	60/375,779 (CON)
Filed on	26 April 2002 (26.04.2002)
US	60/375,622 (CON)
Filed on	26 April 2002 (26.04.2002)

(71) Applicant (for all designated States except US): **GILEAD SCIENCES, INC.** [US/US]; 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ARIMILLI, Murty**, N. [US/US]; 3209 Allerton Circle, Apt. F, Greensboro, NC 27409 (US). **BECKER, Mark, M.** [US/US]; 215 Old County Road, #308, Belmont, CA 94002 (US). **BRYANT, Clifford** [US/US]; 506 Richmond Drive #4, Millbrae, CA 94030 (US). **CHEN, James, M.** [US/US]; 4015 Marblehead Drive, San Ramon, CA 94583 (US). **CHEN, Xiaowu** [US/US]; 377 Laurie Meadows Drive, Apt. 319, San Mateo, CA 94403 (US). **DASTGAH, Azar** [US/US]; 705 San Conrado Terrace #5, Sunnyvale, CA 94085 (US). **FARDIS, Maria** [US/US]; 105 Aberdeen Drive, San Carlos, CA 94070 (US). **HE, Gong-Xin** [CN/US]; 5436 Ontario Common, Fremont, CA 94555 (US). **JIN, Haolun** [CA/US]; 600 Edgewater Blvd., Apt. 102, Foster City, CA 94404 (US). **KIM, Choung, U.** [US/US]; 1750 Elizabeth Street, San Carlos, CA 94070 (US). **LEE, William, A.** [US/US]; 749 Anderson Drive, Los Altos, CA 94024

(US). **LEE, Christopher, P.** [US/US]; 65 Hermann Street, #5, San Francisco, CA 94102 (US). **LIN, Kuei-Ying** [US/US]; 4774 Canvasback Common, Fremont, CA 94555 (US). **LIU, Hongtao** [CN/US]; 1354 Marlin Avenue, Foster City, CA 94404 (US). **MACKMAN, Richard, L.** [GB/US]; 360 Ashton Avenue, Millbrae, CA 94030 (US). **MITCHELL, Michael, L.** [US/US]; 911 Catamaran, #3, Foster City, CA 94404 (US). **NELSON, Peter, H.** [US/US]; 42 San Juan Court, Los Altos, CA 94022 (US). **PYUN, Hyung-Jung** [KR/US]; 35444 Woodbride Place, Fremont, CA 94536 (US). **ROWE, Tanisha, D.** [US/US]; 2708 Mars Hill Street, Modesto, CA 95355 (US). **SPARACINO, Mark** [US/US]; 1450 Seville Drive, Morgan Hill, CA 95037 (US). **SWAMINATHAN, Sundaramoorthi** [IN/US]; 2858 Hillside Drive, Burlingame, CA 94010 (US). **TARIO, James, D.** [US/US]; 142 Elm Street, Apt. 205, San Mateo, CA 94401 (US). **WANG, Jianying** [US/US]; 770 Crane Avenue, Foster City, CA 94404 (US). **WILLIAMS, Matthew, A.** [US/US]; 906 7th Avenue, San Mateo, CA 94402 (US). **XU, Lianhong** [US/US]; 640 Hobart Avenue, San Mateo, CA 94402 (US). **YANG, Zheng-Yu** [CN/US]; 888 Foster City Blvd., Foster City, CA 94404 (US). **YU, Richard, H.** [US/US]; 2625 35th Avenue, San Francisco, CA 94116 (US). **ZHANG, Jiancun** [CN/US]; 5142 Masonic Avenue, Oakland, CA 94618 (US). **ZHANG, Lijun** [CN/US]; 888 Foster City Blvd., E8, Foster City, CA 94404 (US).

(74) Agent: **BOSSE, Mark, L.**; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH

(57) Abstract: Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.

WO 2003/090690 A3



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:
24 June 2004

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/12901

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07F9/40 C07F9/02 C07F9/38

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/04033 A (ARMITAGE IAN GORDON ; SEARLE ANDREW DAVID (GB); GLAXO GROUP LTD (GB) 27 January 2000 (2000-01-27) page 1, paragraph 3; claims 1-4	1,2
X	page 7, line 1 - page 10, line 21; claim 5	130-136
P,A	MENENDEZ-ARIAS L: "Targeting HIV: antiretroviral therapy and development of drug resistance" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 8, 1 August 2002 (2002-08-01), pages 381-388, XP004386181 ISSN: 0165-6147 Fig.1,3; Tab. 1 the whole document	1-14

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

10 March 2004

Date of mailing of the international search report

20. 04. 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Richter, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/12901

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/11906 A (CHASALOW FRED I ;AMUR PHARMACEUTICALS INC (US)) 26 March 1998 (1998-03-26) page 5, lines 25,26; claim 1	1
A	US 5 750 493 A (SCHINAZI RAYMOND F ET AL) 12 May 1998 (1998-05-12) SC-52151, Formula I	1,2
A	ABDEL-MEGUID S S ET AL: "Inhibition of human immunodeficiency virus-1 protease by a C2-symmetric phosphinate. Synthesis and crystallographic analysis" BIOCHEMISTRY 1993 UNITED STATES, vol. 32, no. 31, 1993, pages 7972-7980, XP002257745 ISSN: 0006-2960 .. scheme 1, formula 3, figure 1	1
A	WO 02/14344 A (UNIV KANSAS) 21 February 2002 (2002-02-21) compounds 12, 17b page 1, line 1 - page 6, line 25; examples 6,9,11	1,2, 130-136
A	CLERCQ DE E: "NEW DEVELOPMENTS IN ANTI-HIV CHEMOTHERAPY" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 8, no. 13, November 2001 (2001-11), pages 1543-1572, XP009012547 ISSN: 0929-8673 figure 18	1-3, 15-88, 95,96, 130-136
A	WO 02/06292 A (DU PONT PHARM CO) 24 January 2002 (2002-01-24) page 17	1-3,5, 15-88, 95,96, 130-136
X	EP 0 441 192 A (BAYER A.-G., GERMANY) 14 August 1991 (1991-08-14) page 31; claims 1,8,10; example 18	3
A	DVORAKOVA, HANA ET AL: "Synthesis of 2'-Aminomethyl Derivatives of 9-(2- (Phosphonomethoxy)ethyl) Nucleotide Analogues as Potential Antiviral Agents" JOURNAL OF MEDICINAL CHEMISTRY, 39(17), 3263-3268 CODEN: JMCMAR; ISSN: 0022-2623, 1996, XP002273095 compounds 7,a,b; table 1	3,135

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/12901

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 914 332 A (CHEN XIAOQI ET AL) 22 June 1999 (1999-06-22) claims 77,78	1-3
A	US 5 670 497 A (BOLD GUIDO ET AL) 23 September 1997 (1997-09-23) examples, abstract	3
A	WO 96/14314 A (GILEAD SCIENCES, INC., USA) 17 May 1996 (1996-05-17) examples claim 27 & DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BISCHOFBERGER, NORBERT W. ET AL: "Preparation of thiepane sugars for inhibiting and detecting HIV protease" retrieved from STN Database accession no. 1996:469502 abstract	3
A	US 2001/031773 A1 (CAMDEN, JAMES BERGER) 18 October 2001 (2001-10-18) paragraph '0058!	1-3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/12901

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 130-133, 136
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 130-133, 136 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 92-94, 137-174, 178-200
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,
no additional fees are to be refunded.

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
1-91, 95-122, 130-136
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 130-133, 136 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: 92-94, 137-174, 178-200

In view of the large number and also the wording of the claims presently on file, which render it difficult, if not impossible, to determine the matter for which protection is sought, the present application fails to comply with the clarity and conciseness requirements of Article 6 PCT (see also Rule 6.1(a) PCT) to such an extent that a meaningful search is impossible.

The objections are:

Claim 137 refers back to claim 1 but in claim 1 there is no definition for A3.

In claims 92, and 166 "MBF" is not clear to the skilled person; see for instance WO-A-0114361:

"Example 2: Preparation of Monobenzyl fluorescein (MBF)"

There is no category for a claim directed to an "improvement"; see claim 138 in connection with Guidelines Ch. III. 3.1.

Apart from the fact that the expressions "improvement" or "improved" as such are unclear, the claims 137-165, 178-184 attempt to define the subject-matter in terms of that unclear result to be achieved which merely amounts to a statement of the underlying (unclear) problem. The technical features necessary for achieving this result should have been added.

Claims 189 - 192, 197-199 relate to an undefined pharmaceutical activity which is not in accordance with the requirements of Art. 6 PCT.

The meaning of "half-life" in claims 178- 184, 196 is not precise; see Guidelines Ch. IV. 4.5.

A claim should be understandable without reference to the description. Therefore, claims 166-174, 185 - 188, and 193-195, 200 cannot be accepted under Art. 6, PCT; Rule 6.2(a) and Guidelines Ch. III. 4.10.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: partly: 1,2,130-134,136

Saquinavir - like HIV protease inhibitor compounds and their use

2. claims: partly: 1,2,130-134,136

Lopinavir- like HIV protease inhibitor compounds and their use

3. claims: partly: 1,2,130-134,136

Ritonavir- like HIV protease inhibitor compounds and their use

4. claims: partly: 1,2,130-134,136

Indinavir - like HIV protease inhibitor compounds and their use

5. claims: partly: 1,2,130-134,136

Atazanavir - like HIV protease inhibitor compounds and their use

6. claims: partly: 1,2,130-134,136

Nelvinavir - like HIV protease inhibitor compounds and their use

7. claims: partly: 1,2,130-134,136

Tipranavir - like HIV protease inhibitor compounds and their use

8. claims: partly: 1,2,130-134,136

Amprenavir - like HIV protease inhibitor compounds and their use

9. claims: partly: 1,2,130-134,136

KNI - like HIV protease inhibitor compounds and their use

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. claims: partly: 1,2,130-134,136

Cyclic carbonyl - like HIV protease inhibitor compounds and their use

11. claims: partly: 1,130-134,136

HIV protease inhibitor compounds comprising a phosphonate group which are not comprised by inventions 1-10 and their use

12. claims: 4, partly: claims 3, 15-88, 95, 96,135

compounds of formula I according to claim 3

13. claims: 5, 89-91, 97-113, partly: claims 3,5, 15-88, 95, 96,135

compounds of formula II according to claim 3

14. claims: 6, partly: claims 3, 15-88, 95, 96,135

compounds of formula III according to claim 3

15. claims: 7, partly: claims 3, 15-88, 95, 96,135

compounds of formula IV according to claim 3

16. claims: partly: claims 3,8, 15-88, 95, 96,135

compounds of formula V according to claim 3

17. claims: partly: claims 3,8, 15-88, 95, 96,135

compounds of formula Va according to claim 3

18. claims: 9, partly: claims 3, 15-88, 95, 96,135

compounds of formula VI according to claim 3

19. claims: 10, partly: claims 3,15-88, 95, 96,135

compounds of formula VII according to claim 3

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

20. claims: 11, 114, 115, 118-122, partly: claims 3, 15-88, 95, 96, 135

compounds of formula VIIIa according to claim 3

21. claims: 12, partly: claims 3, 15-88, 95, 96, 135

compounds of formula VIIIb according to claim 3

22. claims: 13, partly: claims 3, 15-88, 95, 96, 135

compounds of formula VIIIc according to claim 3

23. claims: 14, partly: claims 3, 15-88, 95, 96, 135

compounds of formula VIId according to claim 3

24. claims: partly: 123-129

compounds of formula I according to claim 123

25. claims: partly: 123-129

compounds of formula II according to claim 123

26. claims: partly: 123-129

compounds of formula III according to claim 123

27. claims: partly: 123-129

compounds of formula IV according to claim 123

28. claims: partly: 123-129

compounds of formula V according to claim 123

29. claims: partly: 123-129

compounds of formula VI according to claim 123

30. claims: partly: 123-129

compounds of formula VII according to claim 123

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

31. claims: partly: 123-129

compounds of formula VIIIa according to claim 123

32. claims: partly: 123-129

compounds of formula VIIIb according to claim 123

33. claims: partly: 123-129

compounds of formula VIIIc according to claim 123

34. claims: partly: 123-129

compounds of formula VIId according to claim 123

35. claim: partly: 175

HIV protease inhibitor compounds not comprising a phosphonate
or phosphonate prodrug capable of accumulating in human
PBMC's

36. claims: 176-184, partly: 175

HIV protease inhibitor compounds comprising a phosphonate or
phosphonate prodrug capable of accumulating in human PBMC's

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/12901

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0004033	A	27-01-2000	AT 229964 T 15-01-2003
			AU 766056 B2 09-10-2003
			AU 5037999 A 07-02-2000
			BG 105253 A 31-12-2001
			BR 9912156 A 10-04-2001
			CA 2337857 A1 27-01-2000
			CN 1324363 T 28-11-2001
			DE 69904600 D1 30-01-2003
			DE 69904600 T2 13-11-2003
			DK 1098898 T3 07-04-2003
			EA 3191 B1 27-02-2003
			EE 200100038 A 17-06-2002
			WO 0004033 A1 27-01-2000
			EP 1240903 A2 18-09-2002
			EP 1098898 A1 16-05-2001
			ES 2189450 T3 01-07-2003
			HK 1034261 A1 25-07-2003
			HR 20010046 A1 28-02-2002
			HU 0103432 A2 29-04-2002
			ID 28070 A 03-05-2001
			JP 3437553 B2 18-08-2003
			JP 2003521447 T 15-07-2003
			NO 20010282 A 07-03-2001
			NZ 509291 A 30-05-2003
			PL 345620 A1 02-01-2002
			PT 1098898 T 30-04-2003
			SI 1098898 T1 31-08-2003
			SK 762001 A3 08-10-2001
			TR 200100111 T2 21-02-2002
			US 2003100537 A1 29-05-2003
			US 2003096795 A1 22-05-2003
			US 6514953 B1 04-02-2003
			ZA 200100417 A 27-02-2002
WO 9811906	A	26-03-1998	AU 4892897 A 14-04-1998
			CA 2266404 A1 26-03-1998
			EP 0948341 A1 13-10-1999
			JP 2002514183 T 14-05-2002
			US 6127349 A 03-10-2000
			WO 9811906 A1 26-03-1998
US 5750493	A	12-05-1998	AU 716821 B2 09-03-2000
			AU 6860196 A 19-03-1997
			EP 0876387 A1 11-11-1998
			JP 2001500471 T 16-01-2001
			WO 9708180 A1 06-03-1997
WO 0214344	A	21-02-2002	US 6420586 B1 16-07-2002
			AU 8541801 A 25-02-2002
			CA 2419775 A1 21-02-2002
			EP 1311515 A2 21-05-2003
			WO 0214344 A2 21-02-2002
WO 0206292	A	24-01-2002	AU 8063301 A 30-01-2002
			WO 0206292 A1 24-01-2002
			US 2002028791 A1 07-03-2002
EP 0441192	A	14-08-1991	DE 4003574 A1 08-08-1991

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/12901

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0441192	A		EP 0441192 A2	14-08-1991
			JP 4211095 A	03-08-1992
US 5914332	A	22-06-1999	AT 212986 T	15-02-2002
			AU 725369 B2	12-10-2000
			AU 1342297 A	03-07-1997
			BR 1100397 A3	11-04-2000
			CA 2238978 A1	19-06-1997
			CA 2285119 A1	19-06-1997
			CN 1208405 A	17-02-1999
			CZ 9801762 A3	11-11-1998
			DE 69619140 D1	21-03-2002
			DE 69619140 T2	31-10-2002
			DK 882024 T3	21-05-2002
			EP 1170289 A2	09-01-2002
			EP 0882024 A1	09-12-1998
			ES 2173341 T3	16-10-2002
			HK 1016585 A1	09-08-2002
			HU 222731 B1	29-09-2003
			HU 9901079 A2	28-09-1999
			JP 3170292 B2	28-05-2001
			JP 2000502085 T	22-02-2000
			JP 2001058979 A	06-03-2001
			NZ 326132 A	29-11-1999
			PT 882024 T	31-07-2002
			TW 494097 B	11-07-2002
			WO 9721685 A1	19-06-1997
			US 6284767 B1	04-09-2001
			US 2003100755 A1	29-05-2003
			US 6313296 B1	06-11-2001
			US 2002004503 A1	10-01-2002
			CA 2238977 A1	19-06-1997
			EP 1295874 A2	26-03-2003
			EP 0876353 A1	11-11-1998
			JP 2000502997 T	14-03-2000
			WO 9721683 A1	19-06-1997
			ZA 9610475 A	31-07-1997
US 5670497	A	23-09-1997	AU 7491694 A	13-02-1995
			WO 9502582 A1	26-01-1995
			EP 0708760 A1	01-05-1996
			JP 9500120 T	07-01-1997
WO 9614314	A	17-05-1996	US 5705524 A	06-01-1998
			AU 710492 B2	23-09-1999
			AU 4234296 A	31-05-1996
			CA 2203570 A1	17-05-1996
			EP 0789695 A2	20-08-1997
			JP 2002515849 T	28-05-2002
			NZ 297230 A	26-05-2000
			WO 9614314 A2	17-05-1996
			US 6034118 A	07-03-2000
US 2001031773	A1	18-10-2001	US 6258831 B1	10-07-2001
			AU 763573 B2	24-07-2003
			AU 4182200 A	16-10-2000
			CA 2368615 A1	05-10-2000
			EP 1165070 A1	02-01-2002

International Application No
PCT/US 03/12901

Form PCT/ISA/210 (patent family annex) (January 2004)